



## PRESS RELEASE

### PAION AG: ANNUAL GENERAL MEETING ELECTS DR. JÖRG SPIEKERKÖTTER TO THE SUPERVISORY BOARD

SUCCESSOR TO DR. FRANZ A. WIRTZ

Aachen, 22 June 2007 – The biopharmaceutical company PAION AG (FSE: PA8) announced today that Dr. Jörg Spiekerkötter, Berlin (Germany), has been elected to the company's supervisory board by the annual general meeting on 20 June 2007. He replaces Dr. Franz A. Wirtz, co-founder of the company, who will reach the age limit defined for members of the supervisory board of PAION AG this year and who has therefore relinquished his seat. Further members of the board are Dr. Walter Wenninger (chairman), Leverkusen (Germany), and Prof. Dr. Erich Schlick, Otterstadt (Germany).

In addition, the resolutions proposed by the management board and supervisory board were accepted by the annual general meeting with large majorities.

In its constituent meeting, the supervisory board of PAION appointed Prof. Dr. Schlick to its vice chairman.

The supervisory board thanked Dr. Wirtz for his many years of commitment and support as well as his very active contribution to the success and growth of the company.

Dr. Spiekerkötter has many years of experience in the pharmaceutical industry where he has held executive positions in the areas of finance, law and human resources. Until May 2007 he was the Chief Financial Officer of Organon BioSciences N.V., Oss (Netherlands), where he left after the acquisition of the company by the American pharmaceutical company Schering-Plough. Until September 2006 he was the Chief Financial Officer at Schering AG in Berlin (Germany), and before that Head of the Legal Department at Hoechst Schering AgrEvo GmbH in Berlin (Germany). Dr. Spiekerkötter, who has a Ph.D. in law, studied in Bielefeld (Germany), Lausanne (Switzerland) and Freiburg (Germany).

#### **About PAION**

PAION is a biopharmaceutical company based in Aachen, Germany (listed at Frankfurt Stock Exchange, Prime Standard, ISIN DE000A0B65S3). It aims to become a leader in developing and marketing innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need.

#### **Contact**

Dr. Peer Nils Schröder, Investor Relations / Public Relations  
PAION AG, Martinstrasse 10-12, 52062 Aachen – Germany  
Tel. +49 241 4453 152  
E-mail [pn.schroeder@paion.de](mailto:pn.schroeder@paion.de), [www.paion.de](http://www.paion.de)